Clearmind Medicine Inc.

NasdaqCM CMND

Clearmind Medicine Inc. Market Capitalization on January 14, 2025: USD 6.62 M

Clearmind Medicine Inc. Market Capitalization is USD 6.62 M on January 14, 2025, a 38.98% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Clearmind Medicine Inc. 52-week high Market Capitalization is USD 8.26 M on July 15, 2024, which is 24.80% above the current Market Capitalization.
Clearmind Medicine Inc. 52-week low Market Capitalization is USD 3.68 M on January 23, 2024, which is -44.35% below the current Market Capitalization.
Clearmind Medicine Inc. average Market Capitalization for the last 52 weeks is USD 5.25 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: CMND

Clearmind Medicine Inc.

CEO	Dr. Adi Zuloff-Shani Ph.D.
IPO Date	Nov. 15, 2022
Location	Canada
Headquarters	1220 West 6th Avenue
Employees	4
Sector	Health Care
Industries Pharmaceuticals Mental Health

Description

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Key trends

Past 5 years